- Johns Hopkins COVID-19 Dashboard
- Covid Trends
- COVID-19 Testing Project
- How many tests for COVID-19 are being performed around the world?
- Coronavirus Act Now
- Images and B-roll related to the novel coronavirus
Guides and Updates
- The comprehensive Ars Technica guide to the coronavirus – Great questions with answers
- Oregon Health Authority: Emerging Respiratory Infections: COVID-19
- WHO Coronavirus disease (COVID-2019) situation reports
- SSRN Coroniavirus Research
- The Guardian – live coverage of the coronavirus outbreak
- Persistent Symptoms in Patients After Acute COVID-19
- “This study found that in patients who had recovered from COVID-19, 87.4% reported persistence of at least 1 symptom, particularly fatigue and dyspnea.”
- Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study
- “The majority of the Spanish population is seronegative to SARS-CoV-2 infection, even in hotspot areas. Most PCR-confirmed cases have detectable antibodies, but a substantial proportion of people with symptoms compatible with COVID-19 did not have a PCR test and at least a third of infections determined by serology were asymptomatic.”
- Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report (preprint)
- WARNING: Use of “Relative Risk” to inflate claims of effectiveness
- “Dexamethasone reduced deaths by one-third in patients receiving invasive mechanical ventilation (29.0% vs. 40.7%, RR 0.65 [95% CI 0.51 to 0.82]; p<0.001), by one-fifth in patients receiving oxygen without invasive mechanical ventilation (21.5% vs. 25.0%, RR 0.80 [95% CI 0.70 to 0.92]; p=0.002), but did not reduce mortality in patients not receiving respiratory support at randomization.”
- The D614G mutation of SARS-CoV-2 spike protein enhances viral infectivity and decreases neutralization sensitivity to individual convalescent sera (preprint)
- “In this study, we found that the entry efficiency of S-G614 pseudotyped virus was about 2.4 times higher than that of the S-D614 pseudovirus when normalized input virus doses, suggesting that D614G mutation promotes the infectivity of SARS-CoV-2 and enhances viral transmissibility.”
- IgA dominates the early neutralizing antibody response to SARS-CoV-2 (preprint)
- Hydroxychloroquine Proves Ineffective in Hamsters and Macaques Infected with SARS-CoV-2 (preprint)
- Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe Disease (preprint)
- RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis
- “We were unable to confirm a benefit of hydroxychloroquine or chloroquine, when used alone or with a macrolide, on in-hospital outcomes for COVID-19. Each of these drug regimens was associated with decreased in-hospital survival and an increased frequency of ventricular arrhythmias when used for treatment of COVID-19.”
- Full genome viral sequences inform patterns of SARS-CoV-2 spread into and within Israel (preprint)
- “our findings underscore the ability of this virus to efficiently transmit between and within countries, as well as demonstrate the effectiveness of social distancing measures for reducing its spread.”
- No evidence for increased transmissibility from recurrent mutations in SARS-CoV-2 (preprint)
- “There is no evidence at this stage for the emergence of more transmissible lineages of SARS-CoV-2 due to recurrent mutations.”
- Results released for antibody and COVID-19 testing of Boston residents
- “the study to evaluate community exposure to COVID-19 through a representative sampling of asymptomatic Boston residents resulted in 9.9% testing positive for antibodies and 2.6% of currently asymptomatic individuals testing positive for COVID-19.”
- Seroprevalence of SARS-CoV-2–Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020
- “In this community seroprevalence study in Los Angeles County, the prevalence of antibodies to SARS-CoV-2 was 4.65%.”
- Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
- “We propose that reduced innate antiviral defenses coupled with exuberant inflammatory cytokine production are the defining and driving features of COVID-19.”
- EXCESS MORTALITY FROM COVID-19. WEEKLY EXCESS DEATH RATES BY AGE AND SEX FOR SWEDEN. (preprint)
- Serology assays to manage COVID-19
- Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals
- Antibody study shows just 5% of Spaniards have contracted the coronavirus
- Strong Social Distancing Measures In The United States Reduced The COVID-19 Growth Rate
- Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
- “Among patients hospitalized with COVID-19, treatment with hydroxychloroquine, azithromycin, or both was not associated with significantly lower in-hospital mortality.”
- OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients.
- “In summary after full adjustment, death from COVID-19 was strongly associated with: being male; older age and deprivation (both with a strong gradient); uncontrolled diabetes; severe asthma; and various other prior medical conditions. Compared to people with ethnicity recorded as white, black people were at higher risk of death, with only partial attenuation in hazard ratios from the fully adjusted model; with similar findings for Asian people.”
- Press relase: Risk factors for COVID-19 death revealed in world’s largest analysis of patient records to date
- Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19
- “In this observational study involving patients with Covid-19 who had been admitted to the hospital, hydroxychloroquine administration was not associated with either a greatly lowered or an increased risk of the composite end point of intubation or death.”
- Coast-to-Coast Spread of SARS-CoV-2 during the Early Epidemic in the United States
- Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho
- The Risks – Know Them – Avoid Them
- Current development of COVID-19 diagnostics, vaccines and therapeutics
- Repeated seroprevalence of anti-SARS-CoV-2 IgG antibodies in a population-based sample from Geneva, Switzerland (preprint)
- Humoral immune response and prolonged PCR positivity in a cohort of 1343 SARS-CoV 2 patients in the New York City region (preprint)
- “In our sample, we found that 19% of people continue to have nasopharyngeal PCR positivity two or more weeks after symptom resolution, and that it takes three or more weeks to mount an IgG antibody response believed to be potentially protective against future infection. Reassuringly, we found that almost all participants with confirmed SARS-CoV-2 infection in our study mounted an IgG immune response to this disease.”
- Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2 (preprint, highly debated)
- Prolonged presence of SARS-CoV-2 viral RNA in faecal samples
- “Our data suggest the possibility of extended duration of viral shedding in faeces, for nearly 5 weeks after the patients’ respiratory samples tested negative for SARS-CoV-2 RNA.”
- COVID-19 diagnosis and study of serum SARS-CoV-2 specific IgA, IgM and IgG by chemiluminescence immunoanalysis (preprint)
- “Furthermore, the serum IgA level positively correlates with COVID-19 severity.”
- Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
- “In this study of adult patients admitted to hospital for severe COVID-19, remdesivir was not associated with statistically significant clinical benefits.”
- Changes in contact patterns shape the dynamics of the COVID-19 outbreak in China
- Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China
- “In this single-center case series involving 362 patients with hypertension hospitalized with COVID-19 infection, there was no difference in severity of the disease, complications, and risk of death in those who were taking ACEIs/ARBs compared with those not treated with these medications.”
- Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19 (preprint)
- “In this study, we found no evidence that use of hydroxychloroquine, either with or without azithromycin, reduced the risk of mechanical ventilation in patients hospitalized with Covid-19. An association of increased overall mortality was identified in patients treated with hydroxychloroquine alone.”
- Efficient high throughput SARS-CoV-2 testing to detect asymptomatic carriers (preprint)
- Dangers of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence (preprint)
- Patient-derived mutations impact pathogenicity of SARS-CoV-2 (preprint)
- “we provide direct evidence that the SARS-CoV-2 has acquired mutations capable of substantially changing its pathogenicity.”
- A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease (preprint)
- Cytokine release syndrome in severe COVID-19
- COVID-19 Antibody Seroprevalence in Santa Clara County, California (preprint)
- Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19
- Distinct early IgA profile may determine severity of COVID-19 symptoms: an immunological case series (preprint)
- California, Oregon & Washington Announce Western States Pact
- Universal Screening for SARS-CoV-2 in Women Admitted for Delivery
- “Thus, 29 of the 33 patients who were positive for SARS-CoV-2 at admission (87.9%) had no symptoms of Covid-19 at presentation.”
- Indoor transmission of SARS-CoV-2 (preprint)
- “All identified outbreaks of three or more cases occurred in an indoor environment, which confirms that sharing indoor space is a major SARS-CoV-2 infection risk.”
- Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications (preprint)
- “About 30% of patients failed to develop high titers of [neutralizing antibodies] after COVID-19 infection. However, the disease duration of these patients compared to others was similar. Notably, there were ten recovered patients whose [neutralizing antibody] titers were very low, under the detectable level of this study, suggesting that other immune responses, including T cells or cytokines, may contribute to the recovery of these patients. Whether these patients were at high risk of rebound or reinfection should be explored in further studies.”
- Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications (v2 preprint)
- Effectiveness of convalescent plasma therapy in severe COVID-19 patients
- “this pilot study on CP therapy shows a potential therapeutic effect and low risk in the treatment of severe COVID-19 patients. One dose of CP with a high concentration of neutralizing antibodies can rapidly reduce the viral load and tends to improve clinical outcomes.”
- Respiratory virus shedding in exhaled breath and efficacy of face masks
- The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
- Cigarette smoke triggers the expansion of a subpopulation of respiratory epithelial cells that express the SARS-CoV-2 receptor ACE2
- “these results may partially explain why smokers are particularly likely to develop severe SARS-CoV-2 infections, and they suggest that quitting smoking could lessen coronavirus susceptibility.”
- No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection
- Modes of transmission of virus causing COVID-19: implications for IPC precaution recommendations
- H.R.748 – CARES Act – Becomes Law
- Epidemiology and Transmission of COVID-19 in Shenzhen China: Analysis of 391 cases and 1,286 of their close contacts (preprint)
- Potent human neutralizing antibodies elicited by SARS-CoV-2 infection (preprint)
- Integrative considerations during the COVID-19 pandemic
- Oregon Executive Order 20-12: Stay Home, Save Lives: Ordering Oregonians to Stay at Home, Closing Specified Retail Businesses, Requiring Social Distancing Measures for Other Public and Private Facilities, and Imposing Requirements for Outdoor Areas and Licensed Childcare Facilities
- Insights from nanomedicine into chloroquine efficacy against COVID-19
- McConnell’s Response to the Coronavirus Recession Fails Key Tests
- Potential biochemical markers to identify severe cases among COVID-19 patients (preprint)
- SARS-CoV-2 specific antibody responses in COVID-19 patients (preprint)
- “We demonstrate that most PCR-confirmed SARS-CoV-2 infected individuals seroconverted, as revealed by sensitive and specific in-house ELISAs. We found that commercial S1 IgG or IgA ELISAs were of lower specificity while sensitivity varied between the two, with IgA showing higher sensitivity.”
- Rational use of face masks in the COVID-19 pandemic
- H.R.6201 – Families First Coronavirus Response Act – Passes Senate 90-8. Becomes Law.
- A serological assay to detect SARS-CoV-2 seroconversion in humans (preprint)
- “OK, so I promised to explain the manuscript that we just put on medRxiv”
- Video explanation: Stay-at-Home Journal Club #5 – SARS-CoV-2 Antibody Test
- Update 4/16/2020: A serological assay to detect SARS-CoV-2 seroconversion in humans
- published 4/16/2020: SARS‐CoV‐2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup
- How the CDC Botched Basic Science in Its Attempt to Make a Coronavirus Test
- This story is more speculative than the headline makes it sound.
- The coronavirus pandemic in five powerful charts
- What Coronavirus Symptoms Look Like, Day By Day
- SARS-CoV-2 Infection in Children
- Temporal dynamics in viral shedding and transmissibility of COVID-19 (preprint)
- published by Nature 4/15/2020: Temporal dynamics in viral shedding and transmissibility of COVID-19
- What you can learn from looking at Italy vs South Korea on Covid-19
- Important Clarifications Regarding Covid-19 and Natural Medicine
- The proximal origin of SARS-CoV-2
- Efficient inactivation of SARS-CoV-2 by WHO-recommended hand rub formulations and alcohols (preprint)
- Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand
- Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2)
- What we know about the Health Department website cyberattack
- Possible Biological Explanations for Kids’ Escape from COVID-19
- H.R.6201 – Families First Coronavirus Response Act – Passes House (at 1am), Senate adjourned until 3pm Monday March 16th.
- Are high-performing health systems resilient against the COVID-19 epidemic?
- “Three important lessons have emerged. The first is that integration of services in the health system and across other sectors amplifies the ability to absorb and adapt to shock. The second is that the spread of fake news and misinformation constitutes a major unresolved challenge. Finally, the trust of patients, health-care professionals, and society as a whole in government is of paramount importance for meeting health crises.”
- First Oregon COVID-19 Fatality
- Evaluation of the Effectiveness of Surveillance and Containment Measures for the First 100 Patients with COVID-19 in Singapore — January 2–February 29, 2020
- “Singapore has implemented aggressive measures to contain local transmission of COVID-19. After an initial increase in locally transmitted cases, the number of newly identified cases decreased after approximately 1 month, determined by symptom onset dates. This decrease is likely a result of the early implementation of surveillance and detection measures while the numbers of patients were still small and individual-level containment was possible; a larger number of cases would have driven community transmission.”
- Coronavirus: Why You Must Act Now
- Coronavirus: Why it’s so deadly in Italy
- Rep Porter questioning Director of CDC Dr. Redfield
- Oregon Executive Order 20-05: Prohibiting large gatherings due to COVID-19 outbreak in Oregon
- How A Country Serious About Coronavirus Does Testing And Quarantine
- Media briefing on COVID-19 with Dr. Tedros, WHO Director-General
- Colorado Opens Drive-Through Testing Center
- Updated set of COVID-19 Candidate Primers
- Aerosol and surface stability of HCoV-19 (SARS-CoV-2) compared to SARS-CoV-1 (preprint)
- “Our results indicate that aerosol and fomite transmission of HCoV-19 is plausible, as the virus can remain viable in aerosols for multiple hours and on surfaces up to days.”
- Pre-Emptive Low Cost Social Distancing and Enhanced Hygiene Implemented before Local COVID-19 Transmission Could Decrease the Number and Severity of Cases.
- Technical Problems with Existing CDC COVID-19 Primers, and an Improved Set of Primers
- Here Are 17 Ways the Trump Administration Bungled Its Coronavirus Response
- Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes
- Will widespread PCR testing become available to people in the US? If so, when?
- Will Covid-19 antibody testing become available to people in the US? If so, when?
Will the US Congress go on recess (next is Mar 13-22) during the coronavirus outbreak? McConnell has stated that congress will be in session Mar 13-22.
- The Senate adjourned on Mar 12. It is scheduled to resume at 3pm (EDT presumably) Mar 16.
- US Senate Adjourns Mar 26, scheduled to convene Apr 20.
- Will the US Congress pass relief measures that will help people with the economic uncertainty they face? If so, when?
- H.R.6201 – Families First Coronavirus Response Act (aka Phase 2) – Becomes Law on Mar 18.
- House passes H.R.6201 at 1am (EDT) on Mar 14.
- Senate passes H.R.6201 on Mar 18.
- H.R.748 – CARES Act (aka Phase 3) – Becomes Law on Mar 27.
- H.R.6201 – Families First Coronavirus Response Act (aka Phase 2) – Becomes Law on Mar 18.
Will the president declare a national emergency and thus authorize FEMA to use funds and resources for relief?
- Trump declares a state of emergency during press conference on Mar 13 at 3pm EDT.
- Will US state governments move to vote by mail for upcoming elections?